ONC - BeOne Medicines Ltd.

BeOne Medicines Ltd. is a global oncology company focused on developing and commercializing cancer therapies, with its primary commercial product being zanubrutinib (Brukinsa), a next-generation BTK inhibitor approved for B-cell malignancies including chronic lymphocytic leukemia and mantle cell lymphoma. The business model is pharmaceutical prescription drug sales to hospitals, oncology clinics, and specialty pharmacies, with revenue driven by reimbursement from insurers and government health programs. Annual revenue is approximately $1.2–1.5B and growing rapidly, with the United States representing the largest and fastest-growing market, alongside meaningful contributions from China where the company was founded and maintains significant operations. The company remains in a high-growth, reinvestment phase with a broad pipeline of additional oncology assets in clinical development.

Past Year Trends

• BeOne Medicines (formerly BeiGene) completed its redomiciliation to Basel, Switzerland and rebranded from BeiGene to BeOne Medicines in May 2025, changing its Nasdaq ticker to ONC, a structural move aimed at reducing geopolitical risk perception tied to its China origins. (Bullish)
• Full-year 2025 total global revenues reached $5.3 billion, a 40% year-over-year increase, with BRUKINSA (zanubrutinib) alone generating $3.9 billion, up 49% YoY, making it one of the fastest-growing oncology drugs globally and driving the company's first full year of GAAP profitability with diluted EPS of $2.53. (Bullish)
• The U.S. FDA granted Priority Review in November 2025 to sonrotoclax (a BCL2 inhibitor) for relapsed/refractory mantle cell lymphoma, culminating in accelerated FDA approval of BEQALZI (sonrotoclax) on May 13, 2026, making it the first new BCL2 inhibitor approved in the U.S. in a decade and the only BCL2 inhibitor approved in MCL. (Bullish)

Next Year Trends

• BEQALZI (sonrotoclax) received only accelerated FDA approval contingent on the confirmatory CELESTIAL-RRMCL trial (NCT06742996); a failure or delay in that confirmatory readout within the next 12–24 months could result in withdrawal of approval and eliminate the company's second commercial pillar before it scales. (Bearish)
• BeOne raised its full-year 2026 revenue guidance to $6.3–$6.5 billion after Q1 2026 results showed 35% YoY growth and BRUKINSA quarterly revenue of $1.1 billion, with TEVIMBRA contributing $206 million in Q1 2026, suggesting continued double-digit topline compounding if BRUKINSA maintains share against AbbVie's venetoclax-based combinations in CLL. (Bullish)
• The company's BTK degrader BGB-16673 is advancing through clinical trials as a next-generation successor to BRUKINSA targeting BTK-inhibitor-resistant CLL/MCL patients; positive Phase 2 data readouts expected in the next 12 months could materially expand the addressable market and reinforce BeOne's oncology pipeline beyond a single blockbuster dependency. (Bullish)

Red Flags

No severe red flags identified as of August 2025.